Aeterna Zentaris Inc. (NASDAQ:AEZS) traded up 2.8% during trading on Friday . The stock traded as high as $3.74 and last traded at $3.72, with a volume of 68,277 shares traded. The stock had previously closed at $3.62.

Several equities research analysts recently commented on the stock. Canaccord Genuity reiterated a “buy” rating and issued a $9.00 price objective on shares of Aeterna Zentaris in a research report on Tuesday, August 23rd. Zacks Investment Research upgraded shares of Aeterna Zentaris from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research report on Monday, August 15th. Maxim Group reiterated a “buy” rating and issued a $11.00 price objective on shares of Aeterna Zentaris in a research report on Saturday, August 13th. Finally, HC Wainwright reiterated a “buy” rating on shares of Aeterna Zentaris in a research report on Thursday, August 11th.

The stock’s market cap is $36.97 million. The stock’s 50-day moving average price is $3.51 and its 200-day moving average price is $3.51.

Aeterna Zentaris (NASDAQ:AEZS) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.11. Equities research analysts predict that Aeterna Zentaris Inc. will post ($2.61) earnings per share for the current year.

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.